The global gonorrhea diagnostic market is expected to witness a significant growth during the forecast period owing to the growing prevalence of the disease worldwide and unmet need in the faster diagnosis tools. According to the U.S. Center for Disease Control and Prevention (CDC), prevalence rate of gonorrhea was around 106 per million per year in past few years. According to the official data presented by CDC, 333,004 cases of gonorrhea were registered in the U.S. in 2013. It is estimated by CDC that more than 820000 people in U.S. get gonococcal infections each year, yet less than half get reported. In the UK around 28000 cases are reported each year. Lack of awareness about the disease and uncertain symptoms of the disease are the factors expected to aid in the growing prevalence of the disease. Frequent introduction of technologically advanced tools for the detection of the disease causing bacteria and to study lesions is the factor continuing the growth of the market during forecast period. Additionally, development of resistance in gonococcal bacteria owing to the growing number of non-prescription and unlawful usage of antibiotics such as ceftriaxone, doxycyclin and azithromycine used in the management of the disease. Recent reports by the WHO have stated about failure of third line drug cephalosporin in the treatment of gonorrhea especially in the regions such as Japan, Australia and Hong Kong.
Based on the type of the diagnostic test, gonorrhea diagnostic market is segmented into, flow cytometry, diagnostic imaging, gel micro-droplets, artificial intelligence, chromatography, Differential light scattering (DLS), liposomes, monoclonal antibodies, and molecular diagnostics tests. Owing to the advantages associated with it such as ease of doing the procedure, high accuracy and cost for the performance, molecular diagnosis is the most popular and widely used diagnostic test. Monoclonal antibody techniques are used extensively to differentiate between gonorrhea and other diseases with similar symptoms. Flow cytometry has been gaining popularity as an excellent tool for faster diagnosis especially in females, despite the fact that 80% of the infected females fail to show symptoms of the disease. The modern techniques such as artificial intelligence and diagnostic imaging are in the testing phases and expected to dominate the market in the future. Newer technologies for faster and accurate detection of infection are expected to take over the traditional methods for diagnosis and change the market scenario in the future gonorrhea diagnostic market.
Geographically, the gonorrhea diagnostic market is segmented into North America, Europe, Asia Pacific, Latin America, and MEA. North America is currently capturing the largest market share of the market owing to the well developed healthcare infrastructure, and favorable government policies regarding the diagnosis and treatment of the sexually transmitted diseases. High awareness level about the disease and favorable reimbursement policies are the factors expected to boost the market during the forecast period. Market growth in the Asia Pacific region and Middle East is expected to be faster owing to the growing prevalence of the disease in the region and number of unmet needs in effective diagnosis and treatments of the market. Growing awareness about sexually transmitted diseases and the available cure for the same is supposed to help newer diagnostic tools for gonorrhea over traditional method of detection. Rapidly changing lifestyles and involvement of multiple sex partners is the factor anticipated to boost the market in the future. Though weak healthcare structure and low disposable incomes may hamper the market in many countries of the region, the market growth rate is expected to stabilize owing to the growing number of hospitals, commercial labs and newer diagnostic techniques with cost saving and faster procedures.
Major players in the market are Abott Laboratories, F. Hoffmann-La Roche AG, Tosoh Corporation, Siemens AG, bioMérieux, PerkinElmer, Inc., and Ortho Clinical Diagnostics. FDA recently approved Meridian Bioscience developed new molecular amplification test illuminogen HSV I and II in July 2015. Many other companies such as Cigna have been developing faster and innovative diagnostic techniques. Faster and accuracy are the factors expected to make healthcare practitioners frequently upgrade the diagnostic tools and use the latest techniques. This is expected to help new entrants to dominate the market. The scope for new entrants is expected to be tremendous owing to the development in technology and growing numbers of points of care globally.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
ESOMAR & Great Work to Place Certified
ISO 9001:2015 & 27001:2022 Certified
"The quality of research they have done for us has been excellent."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.